Otsuka/Lundbeck's Abilify heir on track for pre-patent cliff approval?
This article was originally published in Scrip
Executive Summary
In an indication of progress with a critical time-sensitive project, Otsuka Holdings' global development partner Lundbeck has said that it expects "headline conclusions" from ongoing Phase III studies with brexpiprazole in the second half of calendar 2013.